Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
2.355 USD +0.64% Intraday chart for Xeris Biopharma Holdings, Inc. +11.61% +0.21%
Jul. 08 Xeris Biopharma Appoints John Shannon as CEO MT
Jul. 08 Xeris Biopharma Holdings, Inc. Announces CEO Changes CI

Evolution of the average Target Price on Xeris Biopharma Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a64a5628f512e6ee2e5fff49e.uGsTGzbAYq-pbHTW3OiS9gqwviqCNJ0JJ9yi7UyG0V8.31wrfHmKNZ_RCTWyt479slXl1VOzWvtxdorGqAjTlx3KEnVEBLQBw-ZZIQ~1b97262e6e544670057131d0944f31e7

Analyst Recommendations on Xeris Biopharma Holdings, Inc.

Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target MT
Craig-Hallum Initiates Xeris Biopharma Holdings at Buy Rating With $4.50 Price Target MT
SVB Securities Trims Xeris Biopharma Price Target to $5 From $6, Maintains Outperform Rating MT
Jefferies Starts Xeris Biopharma Holdings at Buy With $4 Price Target MT
Craig-Hallum Starts Xeris Biopharma Holdings at Buy With $6.50 Price Target MT
Mizuho Securities Adjusts Xeris Biopharma Holdings' Price Target to $6 From $8, Keeps Buy Rating MT
SVB Leerink Adjusts Xeris Biopharma Holdings Price Target to $6 From $8, Maintains Outperform Rating MT
SVB Leerink Raises Price Target on Xeris Biopharma Holdings to $8 From $6, Maintains Outperform Rating MT
HC Wainwright Raises Price Target on Xeris Biopharma Holdings to $5.40 From $4.25, Maintains Buy Rating MT
SVB Leerink Starts Xeris Pharmaceuticals at Outperform With $6 Price Target MT
HC Wainwright Starts Xeris Pharmaceuticals at Buy With $4 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.355 USD
Average target price
4.9 USD
Spread / Average Target
+108.07%
High Price Target
6 USD
Spread / Highest target
+154.78%
Low Price Target
4 USD
Spread / Lowest Target
+69.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Xeris Biopharma Holdings, Inc.

Oppenheimer
Craig-Hallum
SVB Securities LLC
Jefferies & Co.
Mizuho Securities
SVB Leerink
HC Wainwright

Ratings for Xeris Biopharma Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. XERS Stock
  4. Consensus Xeris Biopharma Holdings, Inc.